|Day Low/High||81.67 / 82.24|
|52 Wk Low/High||64.18 / 86.72|
Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.
IBM's busted turnaround and difficult transition story shaved more than 50 points off the Dow, says Jim Cramer.
Stocks close in positive territory Monday ahead of a big week for U.S. corporate earnings.
Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.
JNJ's diabetes and oncology franchises will also be key when the New Brunswick, N.J.-based healthcare giant reports first-quarter numbers Tuesday morning.
Because there are other things that will take the wind out of your sails.
Stocks rise on Monday ahead of a big week for U.S. corporate earnings, including reports Monday from Netlfix and United Airlines.
Stocks rise on Monday ahead of a big week for U.S. corporate earnings and as the U.S. issues a warning to North Korea.
The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.
OncoMed Pharmaceuticals, Incyte and Omeros were among the biotech stock movers in premarket trading on Monday.
The drug was expected to bring in more than $1 billion in sales by 2020.
Stock futures turn higher on Monday ahead of a big week for U.S. corporate earnings and as the U.S. issues a warning to North Korea.
U.S. stock futures are lower Monday following economic data that came in soft and after the U.S. warns North Korea that its patience with the rogue nation is running out.
Doug Kass shares his thoughts on Apple, Allergan and Western Digital.
Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.
Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said that if there is a giant selloff in the broader markets, he likes shares of Eli Lilly LLY.
Eli Lilly has become the new go-to name in the pharmaceutical space, even over Johnson & Johnson, Cramer said.
As advertiser boycotts of 'The O'Reilly Factor' continue to grow, so do analysts' concerns about the network's bottom line. But the impact may be muted for now.
Barclays has an 'overweight' rating on Eli Lilly stock.
We know that we are in the era when index managers are ascendant.